Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
European Biotech Acquisition $220 million combination with Oculis
We advised European Biotech Acquisition on its de-SPAC transaction
Novo Nordisk insulin pricing litigation victory
We prevailed in having the complaint dismissed with prejudice
Envision Healthcare and AmSurg chapter 11 restructuring
We are advising the administrative and collateral agent in connection with AmSurg’s restructuring
Coherus BioSciences $57.5 million follow-on offering
The stock is listed on the Nasdaq Global Market
Envision Healthcare chapter 11 restructuring
We are advising the administrative agent and collateral agent in connection with Envision Healthcare's restructuring
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market